Immunohistochemistry
of human skin using an anti-IgA antibody.
≈ 8 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
of human skin using an anti-IgA antibody. The skin is from a patient with Henoch–Schönlein purpura: IgA deposits are found in the walls of small superficial capillaries (yellow arrows). The pale wavy green area on top is the epidermis, the bottom fibrous area is the dermis.
Immunohistochemistry is a form of immunostaining. It involves the process of selectively identifying antigens in cells and tissue, by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Albert Hewett Coons, Ernest Berliner, Norman Jones and Hugh J Creech was the first to develop immunofluorescence in 1941.
This led to the later development of immunohistochemistry. Immunohistochemical staining is widely used in the diagnosis of abnormal cells such as those found in cancerous tumors. In some cancer cells certain tumor antigens are expressed which make it possible to detect.
Immunohistochemistry is also widely used in basic research, to understand the distribution and localization of biomarkers and differentially expressed proteins in different parts of a biological tissue.
of human skin using an anti-IgA antibody. The skin is from a patient with Henoch–Schönlein purpura: IgA deposits are found in the walls of small superficial capillaries (yellow arrows). The pale wavy green area on top is the epidermis, the bottom fibrous area is the dermis.]]
Immunohistochemistry is a form of immunostaining. It involves the process of selectively identifying antigens in cells and tissue, by exploiting the principle of antibodies binding specifically to antigens in biological tissues. Albert Hewett Coons, Ernest Berliner, Norman Jones and Hugh J Creech was the first to develop immunofluorescence in 1941.
This led to the later development of immunohistochemistry. Immunohistochemical staining is widely used in the diagnosis of abnormal cells such as those found in cancerous tumors. In some cancer cells certain tumor antigens are expressed which make it possible to detect.
Immunohistochemistry is also widely used in basic research, to understand the distribution and localization of biomarkers and differentially expressed proteins in different parts of a biological tissue.
Sample preparation
Immunohistochemistry can be performed on tissue that has been fixed and embedded in paraffin, but also cryopreservated (frozen) tissue. Based on the way the tissue is preserved, there are different steps to prepare the tissue for immunohistochemistry, but the general method includes proper fixation, antigen retrieval, incubation with primary antibody, then incubation with secondary antibody.
Sample labeling
After preparing the sample, the target can be visualized by using antibodies labeled with fluorescent compounds, metals or enzymes. There are direct and indirect methods for labeling the sample.
Antibody types
The antibodies used for detection can be polyclonal or monoclonal. Polyclonal antibodies are made by using animals like guinea pig, rabbit, mouse, rat, or goat. The animal is injected with the antigen of interest and trigger an immune response.
The antibodies can be isolated from the animal's whole serum. Polyclonal antibody production will result in a mixture of different antibodies and will recognize multiple epitopes. Monoclonal antibodies are made by injecting the animal with the antigen of interest and then isolating an antibody-producing B cell, typically from the spleen.
The antibody producing cell is then fused with a cancer cell line. This causes the antibodies to show specificity for a single epitope. For immunohistochemical detection strategies, antibodies are classified as primary or secondary reagents.
Primary antibodies are raised against an antigen of interest and are typically unconjugated (unlabeled). Secondary antibodies are raised against immunoglobulins of the primary antibody species.
The secondary antibody is usually conjugated to a linker molecule, such as biotin, that then recruits reporter molecules, or the secondary antibody itself is directly bound to the reporter molecule.
Counterstains
counterstain.]] After immunohistochemical staining of the target antigen, another stain is often applied. The counterstain provide contrast that helps the primary stain stand out and makes it easier to examine the tissue morphology.
It also helps with orientation and visualization of the tissue section. Hematoxylin is commonly used.
Diagnostic immunohistochemistry markers
targeting the protein CD10.]] Immunohistochemistry is an excellent detection technique and has the tremendous advantage of being able to show exactly where a given protein is located within the tissue examined. It is also an effective way to examine the tissues.
This has made it a widely used technique in neuroscience, enabling researchers to examine protein expression within specific brain structures. Its major disadvantage is that, unlike immunoblotting techniques where staining is checked against a molecular weight ladder, it is impossible to show in immunohistochemistry that the staining corresponds with the protein of interest.
For this reason, primary antibodies must be well-validated in a Western Blot or similar procedure. The technique is even more widely used in diagnostic surgical pathology for immunophenotyping tumors (e.g. immunostaining for e-cadherin to differentiate between ductal carcinoma in situ (stains positive) and lobular carcinoma in situ (does not stain positive) ).
More recently, immunohistochemical techniques have been useful in differential diagnoses of multiple forms of salivary gland, head, and neck carcinomas. The diversity of immunohistochemistry markers used in diagnostic surgical pathology is substantial.
Many clinical laboratories in tertiary hospitals will have menus of over 200 antibodies used as diagnostic, prognostic and predictive biomarkers. Examples of some commonly used markers include: BrdU: used to identify replicating cells. Used to identify tumors as well as in neuroscience research.
Cytokeratins: used for identification of carcinomas but may also be expressed in some sarcomas. CD15 and CD30: used for Hodgkin's disease. Alpha fetoprotein: for yolk sac tumors and hepatocellular carcinoma.
CD117 (KIT): for gastrointestinal stromal tumors (GIST) and mast cell tumors. CD10 (CALLA): for renal cell carcinoma and acute lymphoblastic leukemia.
Prostate specific antigen (PSA): for prostate cancer. estrogens and progesterone receptor (ER & PR) staining are used both diagnostically (breast and gyn tumors) as well as prognostic in breast cancer and predictive of response to therapy (estrogen receptor). Identification of B-cell lymphomas using CD20. Identification of T-cell lymphomas using CD3. , CK-5 and CK-14).
Also, in PIN-4 stained samples, adenocarcinoma cells generally display red cytoplasms (stained by AMACR).]] PIN-4 cocktail, targeting p63, CK-5, CK-14 and AMACR (latter also known as P504S), and used to distinguish prostate adenocarcinoma from benign glands.
Directing therapy
A variety of molecular pathways are altered in cancer and some of the alterations can be targeted in cancer therapy. Immunohistochemistry can be used to assess which tumors are likely to respond to therapy, by detecting the presence or elevated levels of the molecular target.
Chemical inhibitors
Tumor biology allows for a number of potential intracellular targets. Many tumors are hormone dependent. The presence of hormone receptors can be used to determine if a tumor is potentially responsive to antihormonal therapy.
One of the first therapies was the antiestrogen, tamoxifen, used to treat breast cancer. Such hormone receptors can be detected by immunohistochemistry. Imatinib, an intracellular tyrosine kinase inhibitor, was developed to treat chronic myelogenous leukemia, a disease characterized by the formation of a specific abnormal tyrosine kinase.
Imitanib has proven effective in tumors that express other tyrosine kinases, most notably KIT. Most gastrointestinal stromal tumors express KIT, which can be detected by immunohistochemistry.
Monoclonal antibodies
Many proteins shown to be highly upregulated in pathological states by immunohistochemistry are potential targets for therapies utilising monoclonal antibodies. Monoclonal antibodies, due to their size, are utilized against cell surface targets.
Among the overexpressed targets are members of the EGFR family, transmembrane proteins with an extracellular receptor domain regulating an intracellular tyrosine kinase. Of these, HER2/neu (also known as Erb-B2) was the first to be developed. The molecule is highly expressed in a variety of cancer cell types, most notably breast cancer.
As such, antibodies against HER2/neu have been FDA approved for clinical treatment of cancer under the drug name Herceptin. There are commercially available immunohistochemical tests, Dako HercepTest, Leica Biosystems Oracle and Ventana Pathway. Similarly, epidermal growth factor receptor (HER-1) is overexpressed in a variety of cancers including head and neck and colon.
Immunohistochemistry is used to determine patients who may benefit from therapeutic antibodies such as Erbitux (cetuximab). Commercial systems to detect epidermal growth factor receptor by immunohistochemistry include the Dako pharmDx.
Overview of Immunohistochemistry--describes all aspects of immunohistochemistry including sample prep, staining and troubleshooting Immunofluorescent Staining of Paraffin-Embedded Tissue (IF-P) IHC Tip 1: Antigen retrieval - should I do PIER or HIER? Histochemical Staining Methods - University of Rochester Department of Pathology Immunohistochemistry Staining Protocol
Text derived from https://en.wikipedia.org/w/index.php?oldid=1374828963 under CC BY-SA 4.0; modifications have been made.